Kelly, D.; Rose, A.A.N.; Muniz, T.P.; Hogg, D.; Butler, M.O.; Saibil, S.D.; King, I.; Kamil, Z.S.; Ghazarian, D.; Ross, K.;
et al. Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors. Cancers 2021, 13, 3640.
https://doi.org/10.3390/cancers13143640
AMA Style
Kelly D, Rose AAN, Muniz TP, Hogg D, Butler MO, Saibil SD, King I, Kamil ZS, Ghazarian D, Ross K,
et al. Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors. Cancers. 2021; 13(14):3640.
https://doi.org/10.3390/cancers13143640
Chicago/Turabian Style
Kelly, Deirdre, April A. N. Rose, Thiago Pimentel Muniz, David Hogg, Marcus O. Butler, Samuel D. Saibil, Ian King, Zaid Saeed Kamil, Danny Ghazarian, Kendra Ross,
and et al. 2021. "Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors" Cancers 13, no. 14: 3640.
https://doi.org/10.3390/cancers13143640
APA Style
Kelly, D., Rose, A. A. N., Muniz, T. P., Hogg, D., Butler, M. O., Saibil, S. D., King, I., Kamil, Z. S., Ghazarian, D., Ross, K., Iafolla, M., Araujo, D. V., Waldron, J., Laperriere, N., Krema, H., & Spreafico, A.
(2021). Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors. Cancers, 13(14), 3640.
https://doi.org/10.3390/cancers13143640